CA-MCAFEE
Today, McAfee Corp., a global leader in online protection, announced the extension of its ten-year partnership with Samsung, enabling enhanced protection for online threats to consumers’ privacy, identity and personal information.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240723762355/en/
McAfee and Samsung Extend Partnership for 10th Year, Expand AI-Powered Online Protection for Samsung Customers Around the Globe via Galaxy Store (Photo: Business Wire)
Now, Samsung mobile devices, including the Galaxy S24 Ultra, Galaxy S24, Galaxy S24+, Galaxy Tab S9 series, Galaxy Z Flip6, and Galaxy Z Fold6, come with the Galaxy Store pre-installed. This is where users can download and use the McAfee Security app* that includes McAfee Scam Protection™, the company's patented AI technology that automatically identifies and alerts you if it detects a dangerous URL in your text messages. It also proactively blocks risky sites if you accidentally click on a scam link in a text, email, social media post, and more.
In addition to being available on consumer Galaxy phones and tablets, McAfee Security is now available for purchase for existing customers in 98 markets via the Galaxy Store. Consumers can easily buy and install the app on their Samsung mobile device, ensuring uninterrupted online protection. This is particularly important at a time when, with the rise of AI, cybercriminals are creating more convincing, personalized scams at scale, making it harder than ever for consumers to know what content to trust: 50% of mobile phone users say AI has made it harder for them to spot online scams and 39% of respondents admit to having clicked on text scam messages, such as a suspicious text from an unknown number or a fake package delivery text.**
These capabilities also help address key consumer concerns: according to McAfee’s recent Mobile Threat Survey, 90% of people globally are concerned about protecting their online privacy and identity when using their mobile phone. To further combat this concern in the age of AI, the latest Galaxy devices also come equipped with Advanced Intelligence settings***, giving users full control over how much they allow their data to enhance AI experiences by disabling online data processing.
"Our continued partnership with Samsung helps us do what matters most: protect more people so they can live their lives online with confidence," said Pedro Gutierrez, Senior Vice President at McAfee. "With the introduction of Samsung's new mobile AI experience and McAfee's continued focus on using AI to fight against AI scams, we’re thrilled to continue our partnership."
Samsung Galaxy devices, including the Galaxy S24 series, Galaxy Tab S9 series, Galaxy Z Flip6, and Galaxy Z Fold6, now offer McAfee Security with McAfee Scam Protection™ available at a special price through the pre-installed Galaxy Store app. This wide range of available devices with McAfee online protection solutions helps give users comprehensive protection against evolving online threats.
About McAfee
McAfee Corp. is a global leader in online protection for consumers. Focused on protecting people, not just devices, McAfee’s consumer solutions adapt to users’ needs in an always online world, empowering them to live securely through integrated, intuitive solutions that protect their families, communities, and businesses with the right security at the right moment. For more information, please visit https://www.mcafee.com.
_____________________________
* The McAfee Security app available in the Samsung Galaxy Store is McAfee Total Protection™ that includes McAfee Scam Protection, McAfee's patented and powerful Artificial Intelligence (AI) technology that protects against the surge in AI-generated phishing scams.
** McAfee Mobile Threat Survey February 2024 conducted by Market Research Company MSI-ACI with 4,032 adults from 7 countries including the United States, United Kingdom, France, Germany, Australia, India, and Japan.
*** Samsung Account login required. Advanced Intelligence settings preventing server access will limit the functionality of some AI features. Regardless of server access, Samsung does not save user input or output data. Different terms may apply for AI features provided by third parties.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240723762355/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom